Full-Time

Manager – Technical Product Owner

Tpo, Treasury","C&B

Posted on 12/13/2025

Deadline 12/31/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Edison, NJ, USA

In Person

Category
Product (1)
Required Skills
Agile
SAP Products
JIRA
iOS/Swift
Confluence
Requirements
  • Master’s degree in Information Technology or Computer Science.
  • 5 years+ of experience with implementation and maintenance of Treasury solutions (SAP- Cash and Banking, SWIFT, MBC etc).
  • Experience with 1+ full cycle of S/4 HANA implementation for Finance.
  • 2+ years of people management experience.
  • Experience in managing matrix-based project teams including internal resources and contractors.
  • Experience in managing complex global projects, processes and systems.
  • Experience with modern cloud-based application delivery (such as SaaS).
  • Business case/value case management experience.
  • Hands-on disciplined project management skills.
  • Experience with software validation in regulated environments.
  • Working knowledge of core application development principles and SDLC methodology.
  • Demonstrated ability to lead a team and manage work in accordance with full system lifecycle (SDLC) from concept to production deployment.
  • Hands-on experience supporting an application portfolio (post-launch).
  • Proficiency in explaining technologies effectively to customers, communicating technical concepts in non-technical terms.
  • Experience in agile / agile scrum methodology.
  • Experience with agile delivery tools such as Jira and Confluence.
  • Hands on understanding of Design Principles (User Interface and Business Process Mapping).
  • Ability to operate independently and interface with senior business leaders.
  • Ability to communicate at all levels with clarity and precision, both written and verbal.
  • Self-starter with strong teamwork abilities and customer service skills.
  • Extreme focus, attention to detail and delivering high-quality solutions
  • Strong background and experience in virtualization, network and other technologies.
  • Prior experience in supporting global operations and following Enterprise level process frameworks such as ITIL.
  • Note ; the contract is durational (maximum 2 years depending on local regulations) with the possibility to extend.
Responsibilities
  • Sets a clear vision for the product and is responsible for multi-generation product strategy
  • Maximizes ROI by identifying and prioritizing the product features by business value
  • Define, ensure alignment and execute global strategies and solutions; partner with the business to identify opportunities for using technology as an enabler to improve, automate, simplify business processes and optimize total cost of ownership.
  • Continuously manage business partner expectations.
  • Understand the business's needs and priorities from the product
  • Negotiate with the business to see what items (story points) are built and which are backlogged based on capacity
  • Accountable for the development work getting done correctly
  • Participate in the business planning activities by identifying future business demand and ensuring appropriate funding is in the business plan.
  • Drive business process improvement initiatives and champion the change management efforts of Technology initiatives within the business partner community
  • Partner with the business to understand and define business drivers and requirements of the initiated program(s)/project(s). Ensure design gap analysis and prototyping, test script authoring and execution, and deployment activities as needed.
  • Understands development estimates and how levels of effort impact the priority of requirements
  • Tracks progress of all Treasury system development in the context of the larger Treasury project portfolio.
  • Prepare and deliver regular updates and communications (verbal and written) to the Business and Technology Leadership teams, and extended business partners.
  • Has a combination of global and regional accountability depending on product line scope.
  • Ensure Service Level Agreements are established and meet expectations of the business partners.
  • Lead projects of medium to large complexity, and act as Liaison between the various Technology organizations to ensure successful delivery of initiatives to the business partners.
  • Provide coaching/guidance to peers, junior team members, co-ops and/or consultants.
  • Consistently demonstrate knowledge seeking and sharing behaviors across Technology organizational boundaries in the performance of daily work and encourage junior associates to do the same.
  • Apply principles, concepts, and practices of the J&J Leadership Imperatives.
  • Interact with suppliers and vendors to evaluate software, hardware, or services and make recommendations. Partnering with Vendors to ensure compliance with J&J standards, policies and procedures
  • Ensure that J&J information assets are appropriately identified and valued and are protected by complying with and enforcing all local and worldwide security policies.
  • Ensure that security is considered and emphasized in all Technology plans and actions
Desired Qualifications
  • Analytical Reasoning
  • Consulting
  • Cost Management
  • Developing Others
  • Human-Computer Interaction (HCI)
  • Inclusive Leadership
  • Leadership
  • People Performance Management
  • Performance Measurement
  • Product Development
  • Product Strategies
  • Project Management Methodology (PMM)
  • Research and Development
  • Resource Management
  • Software Development Management
  • Strategic Supply Chain Management
  • Team Management

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI and RYBREVANT are driving near-term oncology growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • The Firefly Bio acquisition adds a pan-KRAS oncology platform.

What critics are saying

  • STELARA biosimilar erosion is already cutting a major immunology franchise.
  • Firefly Bio's KRAS platform remains early and can fail clinically.
  • AI surgery and Shockwave launches face adoption, reimbursement, and execution risk.

What makes Johnson & Johnson unique

  • J&J focuses on Innovative Medicine and MedTech after spinning off Kenvue in 2023.
  • Its portfolio spans oncology, immunology, neuroscience, cardiovascular, and surgical robotics.
  • The company combines internal R&D with acquisitions like Abiomed, Shockwave, and Ambrx.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE